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Abstract
Background: Acellular Pertussis vaccines against whooping cough caused by Bordetella pertussis present a much-
improved safety profile compared to the original vaccine of killed whole cells. The principal antigen of acellular Pertussis
vaccine, Pertussis Toxin (PT), must be chemically inactivated to obtain the corresponding toxoid (PTd). This process,
however, results in extensive denaturation of the antigen. The development of acellular Pertussis vaccines containing
PTd or recombinant PT (rPT) with inactivated S1, Filamentous Hemagglutinin (FHA), and Pertactin (PRN) has shown that
the yield of PRN was limiting, whereas FHA was overproduced. To improve antigen yields and process economics, we
have constructed strains of Bordetella pertussis that produce enhanced levels of both rPT and PRN.
Results: Three recombinant strains of Bordetella pertussis were obtained by homologous recombination using an allelic
exchange vector, pSS4245. In the first construct, the segment encoding PT subunit S1 was replaced by two mutations
(R9K and E129G) that removed PT toxicity and Bp-WWC strain was obtained. In the second construct, a second copy of
the whole cluster of PT structural genes containing the above mutations was inserted elsewhere into the chromosome
of Bp-WWC and the Bp-WWD strain was obtained. This strain generated increased amounts of rPT (3.77 ± 0.53 μg/mL)
compared to Bp-WWC (2.61 ± 0.16 μg/mL) and wild type strain (2.2 μg/mL). In the third construct, a second copy of the
prn gene was inserted into the chromosome of Bp-WWD to obtain Bp-WWE. Strain Bp-WWE produced PRN at 4.18 ±
1.02 μg/mL in the cell extract which was about two-fold higher than Bp-WWC (2.48 ± 0.10 μg/mL) and Bp-WWD (2.31 ±
0.17 μg/mL). Purified PTd from Bp-WWD at 0.8-1.6 μg/well did not show any toxicity against Chinese hamster ovary
(CHO) cell whereas purified PT from WT demonstrated a cell clustering endpoint at 2.6 pg/well.
Conclusions: We have constructed Bordetella pertussis strains expressing increased amounts of the antigens, rPT or
rPT and PRN. Expression of the third antigen, FHA was unchanged (always in excess). These strains will be useful
for the manufacture of affordable acellular Pertussis vaccines.
Background
Pertussis or whooping cough is a severe respiratory dis-
ease resulting from colonisation of the upper respiratory
tract by the causative organism Bordetella pertussis [1].
Vaccines have been available for decades, comprising
killed whole cells of B. pertussis that are chemically
detoxified and formulated with Diphtheria and Tetanus
antigens. They are administered as a trivalent Diphtheria-
Tetanus-Pertussis combination, or in newer combina-
tions with HBV and Hib, providing additional immunity
against Hepatitis B and Haemophilus influenzae type b
invasive disease, respectively [2]. The use of whole-cell
Pertussis vaccines has been reduced, discouraged, or even
banned in a few countries, due to the whole-cell vaccine’s
questionable safety profile, resulting from high level of
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killed whole cells [3,4].
Acellular Pertussis vaccines (so-called because they do
not contain whole cells but only partially- or extensively-
purified bacterial antigens), were introduced in Japan in
1981 [5]. The higher purity of the component antigens in
acellular Pertussis vaccines provided an improved clinical
safety profile. These vaccines were introduced in the mid
90 s in other industrialized countries after extensive clini-
cal trials that demonstrated their safety and efficacy [6].
A broader introduction by the WHO into the Expanded
Program of Immunization was, however, hampered by
the significantly higher cost of acellular Pertussis
vaccines.
Am a j o rv i r u l e n c ef a c t o ro fB. pertussis is Pertussis
T o x i n( P T )[ 7 , 8 ]a n dp e r t u s s i st o x o i d( P T d )i ss t i l lt h e
principal antigen in acellular vaccines [8]. Unlike
Diphtheria and Tetanus toxins (that can be inactivated by
simple treatment with formaldehyde), PT proved more dif-
ficult to be inactivated by chemical means [9]. At present,
different inactivation processes are in use for commercial
manufacture of acellular Pertussis vaccines. Unfortunately,
all of them cause extensive denaturation of PT by their
chemical treatments.
Two candidate vaccines have been tested using a geneti-
cally-inactivated toxin (rPT) [10-12] and one of these can-
didates was included in a field efficacy trial [11,12]. This
vaccine was obtained by introducing two mutations into
the catalytic subunit S1 of PT, causing abolition of the
enzymatic activity of S1 and thus providing complete
absence of toxicity of native PT. This vaccine was formu-
lated with 5 μg rPT, 2.5 μg FHA and 2.5 μg PRN and was
compared with another vaccine manufactured using classi-
cal chemical inactivation, comprising 25 μgP T d ,2 5μg
FHA and 8 μg PRN. The two vaccines had identical safety
and efficacy results in this trial [13]. It was understood
that the efficacy obtained with a lower dose of rPT and
the other antigens was a result of using native antigens
that included native FHA and PRN as the latter also
required chemical treatment to inactivate residual traces
o ft o x i nw h e nt h ea n t i g e n sw e r ed e r i v e df r o mw i l dt y p e
B. pertussis.
Unfortunately, the vaccine described above, containing
rPT, is not currently available due to unresolved intellec-
tual property issues at the time of planned commercial
introduction. Nevertheless, it is clear that the genetically-
engineered approach to detoxification of Pertussis vaccine
antigens is an essential element for the design of affordable
acellular Pertussis vaccines, as intellectual property rights
are expiring.
The vaccines referred to above contained three purified
antigens derived from B. pertussis cultures: PTd or rPT,
FHA and PRN. PT and even more so PRN are limiting
antigens in B. pertussis cultures, while FHA is naturally
overproduced. Alternative expression systems exist for
increasing level of limiting B. pertussis vaccine antigens.
PRN was expressed in high yield from recombinant
Escherichia coli or from the recombinant yeast, Pichia
pastoris [14,15]. PT subunits were expressed in E. coli,
but unfortunately these failed to assemble into the
mature toxin and were insufficiently immunogenic to be
considered as potential vaccine candidates [16]. It is now
understood that assembly and secretion of the mature
toxin requires several auxiliary genes that were discov-
ered more recently, and these genes are part of the ptl
section of the ptx-ptl operon [17].
In this publication, we report the construction of
recombinant B. pertussis strains expressing increased
levels of rPT or rPT and PRN. These strains were gener-
ated by a multiple allelic- exchange process: insertion of
the mutations that abolish the catalytic activity of subunit
S1, insertion of a second copy of the ptx cluster of the
five PT structural genes of the ptx-ptl operon with their
promoter and terminator into an abandoned gene else-
where on the chromosome, then insertion of a second
copy of the prn gene into a second inactive gene locus.
The organization of ptl auxiliary genes present in the
ptx-ptl operon was not modified. Enhanced production
of rPT and PRN by manipulation of gene copy number
has been largely used with multi-copy plasmid vectors
and reported to enhance the production of bacterial tox-
ins [18,19], in particular PT [20]. However, genes tan-
demly repeated in this way may have significantly
negative consequences on strain genetic stability in a
GMP-regulated, vaccine-manufacturing environment. In
addition, PRN expression could also be increased by
manipulation of the PRN promoter [21].
The allelic-exchange vectors used in earlier B. pertussis
recombinant strains require mutations on the chromo-
some, particularly the mutation affecting rpsL that results
from selection of spontaneous streptomycin-resistant
mutants as required in earlier allelic-exchange proce-
dures [22]. Such mutations affecting housekeeping genes
may impair virulence, hence the expression of virulence
factors including PT, FHA and PRN. In contrary,
pSS4245 used in this study harbours streptomycin resis-
tant gene from Tn5 which is functional in B. pertussis
but not in E. coli, hence streptomycin was used to select
against E. coli donor cell and I-SceI nuclease activity in
the plasmid was then functioned as the counter selectable
marker in the recombinant B. pertussis through subse-
quent homologous recombination and does not require
or leave auxiliary mutations. The strains reported here
produce unaltered levels of the other antigens in particu-
lar FHA. These constructs will prove useful for the man-
ufacture of affordable human acellular Pertussis vaccines.
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Mutation of the S1 gene in the B. Pertussis chromosome
To introduce the two mutations R9K and E129G into the
S1 subunit, a two-stage approach was used to avoid the
possibility of recombination in the region between the two
mutations that would cause the loss of one of the muta-
tions. This approach also allowed selection of the desired
colonies by simple replica plating on selective media.
Firstly, two E. coli vectors were constructed in pBluescript
II SK + where the wild-type S1 gene was replaced by a
chloramphenicol resistance gene (Cm
R) (Figure 1A) or by
am o d i f i e dS1 gene including the desired mutations
(Figure 1B); both flanked by 1.2 and 1.5 kb of the S1
upstream and downstream regions, respectively. These
vectors were then processed and their inserts were intro-
duced into pSS4245. These derivatives were transferred
into E. coli SM10 for conjugative transfer and allelic
exchange into B. pertussis strain Tohama. The plasmid
pSS5Cm3 generated a replacement of the S1 gene by the
Cm
R marker (Figure 2A). The plasmid pSS5S13-9 K-129
G restored the S1 gene into its original location, now with
the two desired mutations (Figure 2B). After selection of
isolates on selective media, integration of the Cm
R and
modified S1 genes at the expected position was confirmed
by PCR amplification (data not shown). The integration of
the mutated S1 gene at the designated position was con-
firmed by PCR with specific primers that could hybridize
the upstream 5 and 3 prime downstream flanking regions
and internally in the S1 gene (data not shown). The muta-
tions in the S1 gene of the clone selected for further
manipulation was confirmed by DNA sequencing. The
new strain was designated as Bp-WWC.
Insertion of a second integration site for a second set of
PT structural genes
Initial attempts to increase PT expression by inserting
the whole ptx-ptl operon into a multi-copy plasmid com-
patible with B. pertussis failed to deliver useful strains
suggesting that the over-expression of PT is potentially
toxic and must remain within certain limits to obtain
viable strains. In order to increase the PT toxin yield, a
second set of PT structural genes was introduced into
the Bp-WWC chromosome. To identify an insertion tar-
get site, the sequence of the B. pertussis Tohama genome
(accession number NC_002929) was scanned and many
pseudogenes were identified. The DNA sequence (posn.
2905288) between a putative ammonium transporter
gene and a putative auto-transporter gene was selected
Figure 1 Vectors for the construction of a modified S1 gene into the allelic-exchange vector pSS4245. A: Allelic-exchange element for
replacing the S1 gene by a chloramphenicol resistance cassette, inserted between the S1 flanging regions. B: Allelic-exchange element for
returning the modified S1 gene into its exact location in the ptx-ptl operon. To obtain the allelic exchange, these vectors were linearized and
inserted into pSS4245, which was then introduced into B. pertussis by conjugative transfer from E. coli SM10
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2908277). These genes each carry frameshift mutations
which ruin their functionality (Figure 3A). The general
strategy outlined in the preceding section was followed.
First, the E. coli vector pSKPD5Cm3 was constructed by
inserting the Cm
R gene within the regions flanking the
selected integration site (Figure 3B). After insertion of
the sequences of interest into pSS4245, allelic exchange
Figure 2 Allelic-exchange procedure. A: Double recombination events leading to the replacement of the S1 gene by a chloramphenicol
resistance marker. B: Double recombination events leading to the re-insertion of the modified S1 gene in its original location.
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Page 4 of 16Figure 3 Vectors for the insertion of a second copy of the ptx operon into the B. pertussis chromosome. A: The insertion site for a
second copy of the ptx operon was selected between two abandoned genes, each carrying two frameshift mutations. B: Allelic-exchange
elements used to insert a chloramphenicol marker into the selected site. C: Schematic structure of the ptx operon with its original promoter. The
ptx-ptl terminator was cloned and inserted downstream of the S3 gene. This cluster was finally integrated into the SS4245 derivative to replace
the chloramphenicol marker and generate the second allelic-exchange event to insert the second copy of the PT structural genes.
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R marker. Integration of the Cm
R
gene at the designated position was confirmed by PCR
(data not shown). In the second vector, five PT structural
genes with mutated S1 were inserted between the ptx-ptl
operon promoter and terminator (following the S3 gene)
to generate the vector pSKptxter (Figure 3C). Allelic
exchange into the selected target integration inserted a
second copy of the functional cluster of the PT structural
genes into Bp-WWC strain. The new strain was desig-
nated as Bp-WWD. This strain harboured two copies of
ptx operon with mutated S1 gene. The result of integra-
tion was verified by amplification of the upstream, down-
stream, and internal regions of the ptx operon, that all
showed the expected integration without disruption of
the regions where recombination had occurred.
Sequencing of the S1 gene and identification of the R9K
and E129G mutations
Automated sequencing was applied to confirm the pre-
sence of the desired mutations. In the case of strain Bp-
W W Dt h a th a st w oi n t e g r a t e dc o p i e so ft h eS1 gene,
PCR amplification yields, in principle, a mix of the
copies of the two genes. An unexpected point mutation
in one of the inserts would appear as a double-nucleo-
tide assignment at the corresponding position. The sin-
gle peak of fluorescence signal at the R9K and E129G
positions indicated the correct sequence on Bp-WWC
and that of the two copies of S1 in Bp-WWD had iden-
tical mutations. The sequence around the two desired
mutations is reported in Figure 4 that shows the
sequencing records for strain Bp-WWD and the
sequence alignments for wild-type Tohama, Bp-WWC
and Bp-WWD.
Insertion of a second copy of the prn genes into the Bp-
WWD strain
Due to the low level of PRN expression, a second copy of
the prn structural gene (under control of the 246 bp fha
promoter and its own terminator) was introduced into the
Bp-WWD chromosome (posn. 1345693) between the two
pseudogenes of putative exported dehydrogenase (posn.
1344710-1345685) and a putative aspartate racemase
(posn. 1345693-1346049) (Figure 5A). The pSKPD2Cm3
E. coli vector was constructed where the Cm
R gene was
inserted between the upstream and downstream regions
flanking the selected insertion site. Another vector was
constructed using the same flanking regions and the prn
gene under control of the fha promoter (Figure 5B). After
insertion of the Cm
R marker in the desired location, the
Cm
R gene was replaced by the prn functional block using
the usual allelic-exchange selection and screening
procedures.
The B. pertussis strains isolated from this construction
exercise did not express PRN and the expression level of
the other (FHA, PT and hemolysin) antigens was not
detectable (data not shown). It was tentatively concluded
that the PRN product is toxic if overproduced under
control of the stronger fha promoter and only escape
mutants having lost the capacity to produce PRN or all
virulence factors were viable. It was, therefore, decided
to introduce the natural prn promoter in place of the
fha promoter. The plasmid pSKPD25FpPRN3 was used
to replace the fha promoter by the original prn promo-
ter to generate a functional cassette with its own natural
promoter and terminator (Figure 5C). This functional
cassette was inserted at the selected site by the usual
allelic-exchange procedure to obtain a strain with a sec-
ond non-tandemly-repeated copy of the prn gene under
control of its own promoter. The expected insertion was
confirmed by PCR amplification with primers binding to
the flanking regions internally in the prn gene. This
strain was normally viable and was designated as Bp-
WWE.
Genetic stability of PT and PRN constructs in Bp-WWE
The strain Bp-WWE was cultured and serially sub-cul-
tured in Modified Stainer-Scholte (MSS) medium to reach
approximately 50 generations. The last culture was diluted
and plated onto MSS agar. Thirty isolated colonies were
randomly picked, and analyzed for their S1 and prn genes
by PCR (data not shown). The results showed that all
colonies contained two copies of S1 and prn genes at the
expected positions.
Expression of PT, FHA and PRN in shake flasks
The production of PT and FHA in shake flask cultures
was analyzed by ELISA. Shake flask cultures were all per-
formed in MSS medium containing heptakis(2,6-O-
dimethyl)b-cyclodextrin [23,24]. At 36 h, the production
of PT was about doubled in strain Bp-WWD (3.77 ± 0.53
μg/mL), compared with Bp-WWC (2.61 ± 0.16 μg/mL)
and wild-type Tohama (2.2 μg/mL) (Table 1), demonstrat-
ing that the level of PT expression was a function of the
number of copies of the structural gene cluster. FHA in all
three recombinant strains was about the same (Table 1).
The production of PRN in shake flask cultures of Bp-
WWC, Bp-WWD and Bp-WWE in MSS medium was
analyzed by densitometry analysis of Western blot results.
PRN amount in the clarified culture supernatants and
extract of the separated cells at 60°C was assayed. The
amount of PRN in cell extract of Bp-WWC and Bp-WWD
was similar (2.48 ± 0.10 and 2.31 ± 0.17 μg/mL, respec-
tively). A two-fold increase was found in Bp-WWE (4.18 ±
1.02 μg/mL), again showing a good correlation of the level
of prn expression to the gene copy number. In all three
recombinant strains, the fraction of PRN found in the
supernatant fraction in these flask cultures was small or
negligible (less than 0.1 μg/mL, data not shown).
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Page 6 of 16Figure 4 Identification of the R9K and E129G mutations in Bp-WWC and Bp-WWD. Raw sequence data around the mutations are shown
for strain Bp-WWD that has two copies of the PT structural cluster. The corresponding sequence alignments are shown for B. pertussis Tohama
(consensus sequence) and derivatives Bp-WWC and Bp-WWD.
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PT was purified from culture supernatants using a mod-
ification of the process published by Ozcengiz [25]
where the initial ammonium sulphate precipitation was
replaced by ligand exchange chromatography [26,27].
The toxicity of the PT toxin from wild type B. pertussis
and Bp-WWC (genetically inactivated PT) was analysed
and compared by the Chinese hamster ovary (CHO) cell
clustering assay [28]. This assay has a much higher sen-
sitivity than other functional assays reported for PT.
The native toxin purified from strain B. pertussis
Tohama demonstrated a clustering endpoint at 2.6 pg
Figure 5 Vectors for the insertion of a second copy of the prn gene into the B. pertussis chromosome. A: The insertion site for a second
copy of the prn gene was selected between two abandoned genes carrying frameshift mutations and a deletion. B: Schematic structure of the
prn gene under control of fha promoter and flanking with target integration site. C: Schematic structure of the prn gene under control of its
own promoter and flanking with target integration site.
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clustering at the highest concentrations of 0.8-1.6 μg per
sample obtained in this test (Figure 6). This assay can,
therefore, detect toxicity reduction by a factor of 5 ×
10
5 to 1 × 10
6, despite limitations imposed by the low
solubility of PT. This result demonstrated that PT toxin
purified from Bp-WWC was successfully inactivated by
insertion of five nucleotide replacements resulting in
two amino acid replacements in the PT subunit S1.
Discussion
Unmarked gene insertion and replacement were success-
ful, using pSS4245 as vector in B. pertussis. After a second
homologous recombination to excise the plasmid, no
antibiotic gene marker nor any scars were left in the chro-
mosome when compared with the cre-lox system [29] or
earlier allelic-exchange procedures used in Bordetella [22].
Overproduction of genetically-deactivated PT toxin was
reported in 1992 [20] by using tandem repeats of ptx
genes or another copy inserted into the fha gene. The
resulting recombinant B. pertussis strain overproduced PT
up to 80 mg/L. Tandemly-repeated genes are a known
potential cause of genetic instability. For this reason, the
genome sequence of B. pertussis was scanned to look for
suitable integration sites. The DNA position between two
terminators of pseudo-genes (putative ammonium trans-
porter and putative auto-transporter genes) was selected
as integration sites for the ptx cluster. The copy number
for the PT structural cluster was limited to two, as over-
production of these virulence factors places a burden on
cell metabolism, resulting in slower growth and potentially
genetic instability, as shown by preliminary results.
Over-expression of prn gene by the fha promoter to
drive higher expression was apparently toxic to growth of
B. pertussis, possibly in resulting from higher PT expres-
sion. Our results showed that replacement of the prn
promoter with a stronger one did not provide increased
prn expression [21]. Therefore, increasing the gene copy
number under the control of the native prn promoter
was the approach selected. The fha promoter of the
Table 1 PT, FHA and PRN production by strains Bp-WWC
and Bp-WWD and Bp-WWE
Strain PT (μg/mL) FHA (μg/mL) PRN (μg/mL)**
Tohama wt 2.2 ND* ND*
Bp-WWC 2.61 ± 0.16 17.75 ± 3.30 2.48 ± 0.10
Bp-WWD 3.77 ± 0.53 14.33 ± 0.50 2.31 ± 0.17
Bp-WWE 4.49 ± 0.83 17.08 ± 2.21 4.18 ± 1.02
*ND = Not determined **The amount in cell extract
The values were the mean of 3 independent experiments with standard
deviation except the data for PT of Tohama WT was obtained from two
independent experiments
Figure 6 CHO-cell clustering test. The cells were grown to near confluence then dilutions of PT were added and the clustering was scored
after 2 days. A: 800 ng PT (strain Bp-WWC). B: Control, no PT added. C: 2.6 pg wt PT (strain Tohama) corresponding to the limit of detection. D.
43 pg wt PT (strain Tohama)
Buasri et al. BMC Microbiology 2012, 12:61
http://www.biomedcentral.com/1471-2180/12/61
Page 9 of 16second gene copy was replaced by the native prn promo-
ter to generate a strain with a second copy of the prn
gene and its native promoter inserted into another loca-
tion on the chromosome. The toxicity of PRN to the host
cell was also reported in E. coli [30]. The fha promoter
was then replaced by the native prn promoter, then the
resulting strain exhibited normal growth in shake flasks
and expressed twice the amount of PRN. The distribution
of PRN between culture supernatant and cell extract was
modified - a larger fraction of total PRN was found in the
supernatant although in shake flasks, the quantities of
PRN spontaneously released into the supernatant were
minimal. The presence of either two copies of mutated
PT gene alone or together with two copies of prn in
WWC, WWD or WWE did not show any genetic
instability as evidenced by serial-subculture experiment.
All recombinant strains showed the presence of two
copies of corresponding genes and corresponding
amount of PT and PRN. Hence, homologous recombina-
tion among the homologous copies was not so far found
in these strains.
Although bacterial growth in shake-flask culture is lim-
ited due to rapid pH rise and intoxication from release of
ammonia by metabolism of the glutamate carbon source
[31], shake-flask culture provides a useful indication of the
strain’s potential under optimized fermentor conditions.
The construction of stable strains with enhanced expres-
sion of PT (Bp-WWD) or of the two limiting antigens PT
and PRN (Bp-WWE) was demonstrated. With enhanced
production of PT alone, Bp-WWD could not generate suf-
ficient quantities of PRN, therefore in this case, the use of
an independent supply of PRN in recombinant E. coli or
P. pastoris would be required. As the expression level of
both PT and PRN has been equally increased in strain Bp-
WWE, it would be expected that matching quantities of
the two antigens would also be obtained in higher-density
cultures, thereby simplifying vaccine manufacturing
operations.
Conclusions
B. pertussis strains that contains genetically-inactivated
S1::R9K-E129G subunits of PT were constructed without
leaving any markers or scars in their chromosomes. An
about two-fold increase in expression of PT toxin was
found in shake flasks by integrating the 5 structural
genes (ptx with S1 mutated) under the control of the ptx-
ptl operon promoter and terminator between two
pseudo-genes on the chromosome. The presence of
detoxified PT was confirmed by the CHO cell clustering
assay. In addition, PRN production was increased by inte-
gration of a second copy of the prn gene between other
pseudo-genes located elsewhere on the chromosome.
The strains were found to be genetically stable in shake
flask sub-cultures at higher generation numbers than
would be required to reach large-scale fermentations (>
1,000 L). These recombinant strains, in particular, strain
Bp-WWE (where the ratio of expression of PT and PRN
antigens matches the composition of commercial Pertus-
sis vaccines), should enable production of affordable acel-
lular Pertussis vaccines. The lower Cost of Goods (CoG)
is provided by the lower dose of native antigens required
for adequate immunogenicity and the higher productivity
the two limiting antigens PT and PRN.
Methods
Bacterial strains, plasmids and culture conditions
All chemicals and reagents used in this study were either
molecular biology or analytical grade. Chemicals were
purchased from Merck (Germany) and Sigma (USA).
Bacterial culture media were obtained from Difco (USA)
and Merck. Restriction and modifying enzymes were pur-
chased from New England Biolabs (USA).
E. coli DH5a (Invitrogen, USA) was used as a cloning
host. This strain was grown at 37°C in Luria Bertani (LB)
medium. The E. coli DH5a transformants were grown in
LB medium supplemented with appropriate antibiotics:
amplicillin (50 μg/mL) or chloramphenicol (15 μg/mL).
E. coli SM10 and pSS4245 were obtained from Dr. Earle
S. Stibitz and used as a conjugative donor strain and an
allelic exchange vector, respectively. This strain was
grown at 37°C in LB medium supplemented with kana-
mycin (50 μg/mL). The E. coli SM10 transformants were
grown in LB medium supplemented with kanamycin (50
μg/mL), amplicillin (50 μg/mL) and neomycin (10 μg/
mL). B. pertussis Tohama was obtained from ATCC
(BAA-589). B. pertussis strains were grown at 35°C on
Bordet-Gengou (BG) agar or MSS medium [32]. One
liter of the MSS medium contained 10.7 g of monoso-
dium glutamate, 0.24 g of L-proline, 2.5 g of NaCl, 0.5 g
of KH2PO4,0 . 2go fK C l ,0 . 1go fM g C l 2·6H2O, 0.02 g of
CaCl2·2H2O, 6.1 g of Tris base, 10 g of casamino acids
0.01 g of FeSO4·7H2O, 0.04 g of L-cysteine, 0.1 g of glu-
tathione, 0.02 g of ascorbic acid, 0.004 g of niacin and 1 g
of dimethyl-b-cyclodextrin. Plasmidp B l u e s c r i p tI IS K+
and pACYC184 were obtained from Stratagene (USA)
and New England Biolabs (USA), respectively.
Cloning of S1 flanking regions and insertion of a
chloramphenicol gene
The chromosomal DNA of B. pertussis strain Tohama
was used as source material. The upstream region of the
S1 gene was amplified by PCR using the 5’F-PT-SalI and
5’R-PT-MCS primers. The latter contained KpnI, XbaI,
BglII and NotI sites. The amplification product was
recovered from agarose gel and purified by QIAEX II
Extraction kit (Qiagen, Germany). The 1287 bp amplifi-
cation product was digested with SalIa n dNotIa n d
cloned into the E. coli vector pSKΔKpnI digested with
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Page 10 of 16t h es a m ee n z y m e s .p S K ΔKpnI was a derivative of pBlue-
script II SK + where the KpnI site was removed by diges-
tion, trimming 3’ protruding end by the Klenow enzyme,
and re-circularization. The resulting construct was trans-
formed by heat shock into competent cells of E. coli
DH5a and designated as pSK5’. The downstream region
was likewise obtained by amplification with the 3’F-PT-
XbaI and 3’R-PT-BglII primers. The 1531 bp product
was digested with XbaIa n dBglII and the recovered frag-
ment inserted into pSK5’ digested with the same enzymes
to obtain pSK53.
The Cm
R gene was obtained from plasmid pACYC184.
T h eg e n ew a sa m p l i f i e du s i n gt h ep r i m e r sC m F - K p n I
and CmR-XbaI. The 1295 bp PCR product was purified
and digested with KpnIa n dXbaI and inserted into
pSK53 cut with the same enzymes. The resulting plas-
mid was designated as pSK5Cm3. This plasmid incorpo-
rated the chloramphenicol resistance gene flanked by
the 5’-upstream and 3’-downstream regions of the S1
gene (Figure 1A).
Exchange of the S1 gene by homologous recombination
To perform the allelic exchange, vector pSS4245 [33] was
used. Plasmid pSK5Cm3 was digested with SacI and BglII
and the recovered fragment ligated into pSS4245 cut
with SacIa n dBamHI. After transformation into E. coli
SM10, the resulting plasmid was designated as pSS5Cm3.
Fresh cultures of B. pertussis strain Tohama (4 days on
MSS-agar with 20 mM nicotinic acid) and of E. coli
SM10 harbouring the vector (overnight on LB-agar with
ampicillin, kanamycin and chloramphenicol) were
scraped and mixed onto agar plates containing LB:MSS
(1:1) with 20 mM nicotinic acid and 10 mM MgCl2. After
3 h-cultivation at 35°C, the mix was swabbed onto MSS
with 20 mM nicotinic acid, 50 μg/mL streptomycin and
5 μg/mL chloramphenicol. Streptomycin and chloram-
phenicol were used to select against E. coli SM10 (donor
cell) and B. pertussis (recipient cell). The swab growth
was streaked onto MSS agar with 5 μg/mL chloramphe-
nicol for the second recombination event. The resulting
single colonies were tested by replica plating and a few
colonies with the Sm
S and Cm
R phenotype were retained
for further testing (Figure 2A). The integration of Cm
R
gene at designed position was confirmed by PCR using
the primers that specifically bind to the upstream 5’ (5’F-
int and 5’RCM-int primers) and 3’ (3’FCM-int and 3’R-
int primers) downstream flanking regions and internally
in the Cm
R gene. From the PCR analysis, it was con-
firmed that the 5’ and 3’ flanking regions were present
and the Cm
R gene had been inserted at the expected
location in place of the S1 gene. These verifications also
confirmed that the allelic-exchange process had not
caused any alteration in the S1 flanking regions where
recombination had taken place.
Construction of a modified S1 gene
The S1 gene was cloned by PCR amplification and
mutated by site-directed PCR mutagenesis. The primers
S1F-PT-KpnI and S1R-PT-XbaI (Table 2) were used to
amplify the gene from chromosomal DNA. The purified
PCR product was digested with XbaIa n dKpnIa n dt h e
recovered 908 bp fragment was ligated into pSK53 cut
with the same enzymes. After transformation and colony
selection, the resulting plasmid was designated as
pSK5S13.
Site-directed PCR mutagenesis used the internal F-R9K
and R-R9K primers with the sequence mismatch
CGC®AAG, causing the R9K substitution. The same pro-
cedure was applied to generate the second mutation using
the internal mismatched primers F-E129G and R-E129G,
to generate the sequence GAA®GGG, causing the E129G
substitution.
The resulting fragment was digested with XbaIa n dKpnI
and inserted into pSK53 cut with the same enzymes to
obtain plasmid pSK5S13-9 K-129 G (Figure 1B). This was
digested with SacIa n dBglII and the recovered fragment
was ligated into pSS4245 cut with SacI and BamHI. After
transformation into E. coli SM10, the resulting plasmid
was designated as pSS5S13-9 K-129 G.
Allelic exchange to insert the modified S1 gene back into
its original location in the B. pertussis chromosome was
performed as above but without selection of the exconju-
gants by chloramphenicol. The desired strains in this case
have lost this marker and therefore screening by replica
plating was necessary to identify colonies with the desired
phenotype Cm
S and Sm
S. The resulting Tohama derivative
was designated as Bp-WWC (Figure 2B). The integration
of the S1 mutated gene at the designated position was
confirmed by PCR with the specific primers. The primers
could bind the upstream 5’ (5’F-int and R-R9K primers), 3’
(F-E129G and 3’R-int primers) downstream flanking
regions, and inside the S1 gene.
Insertion of a second set of the 5 PT structural genes
The sequences flanking the targeted insertion site (Figure
3A) were first cloned to obtain pSKPD5Cm3. The
upstream 1688 bp fragment was amplified with the pri-
mers 5’F-PD-ApaI and 5’R-PD-MCS, digested with ApaI
and KpnI, and ligated into pSK5Cm3 cut with the same
enzymes to yield pSKPD5’-Cm. The downstream 2980 bp
fragment was amplified with the primers 3’F-PD-MCS and
3’R-PD-BglII, digested with XbaIa n dBglII, and ligated
into pSKPD5’-Cm cut with the same enzymes. The result-
ing plasmid was designated as pSKPD5Cm3 (Figure 3B).
The conjugative construct was obtained by digesting this
plasmid with NotIa n dBglII and ligation into pSS4245
which was digested with NotIa n dBamHI, resulting in
plasmid pSSPD53-Cm. Conjugative transfer and selection
for Sm
S and Cm
R provided the desired B. pertussis
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upstream, downstream, and Cm
R insert was confirmed by
PCR amplification. The primers could bind the upstream
5’ (5’FPD-int and 5’RCM-int primers), 3’ (3’FCM-int and
3’RPD-int primers) downstream flanking regions, and
inside the Cm
R gene.
Table 2 Primers used for construction
Name Sequence
5’F-PT-SalI GCGGTCGACGGCGCGCAATGCGGCGCGGAC
5’R-PT-MCS GGGGGCGGCCGCGAGATCTCTCTAGACGGTACCATCGCGCGACTTTGCGCCGAAGGA
3’F-PT-XbaI CGTTCTAGACCTGGCCCAGCCCCGCCCAAC
3’R-PT-BglII GGCAGATCTGCAGTTCGAGCAGATCGCCGG
CmF-KpnI CGCGGTACCTGATGTCCGGCGGTGCTTTTG
CmR-XbaI AATCTAGATATCGTCAATTATTACCTCCAC
S1F-PT-KpnI GATGGTACCGGTCACCGTCCGGACCGTGCT
S1R-PT-XbaI CAGGTCTAGAACGAATACGCGATGCTTTCG
R-R9K GGGCGGGAGTCATACTTGTATACGGTGGCGG
F-R9K CCGCCACCGTATACAAGTATGACTCCCGCCC
F-E129G CCACCTACCAGAGCGGGTATCTGGCACACCGG
R-E129G CCGGTGTGCCAGATACCCGCTCTGGTAGGTGG
5’F-PD-ApaI GGAGGGCCCATGAAACTCGTCATCGCCATCATCAAGCCC
5’R-PD-MCS TACGGTACCGGATCCCGCATCGCAACAACGGGGTCATCGCGACCC
3’F-PD-MCS CGTTCTAGAACTAGTCCGCTACCAGGTGTAGCGATAGCCCAGGTG
3’R-PD-BglII TGTAGATCTCGGCGAGATACTTGCGTTTCGGCGTTGTCG
PtxF-BamHI TTGGGATCCCAGCGCAGCCCTCCAACGCGCCATCC
PtxR-MCS TCTACTAGTAAGAATTCTCGCGGTATCCGTCAAGGAAAAACATGGAC
TerF-EcoRI GCGGAATTCCGCCTGCCGCCTGCACGCAT
TerR-SpeI TCCACTAGTCAAGGGCATCGGGCGCCGGC
5’F-PD2-SpeI CGCACTAGTCTATTCCAGCGGCGGGTCGAAATGGC
5’R-PD2-MCS CCCCAGGCGGCCGCTGTCTAGAGTGGATCCCAGGCCGATGCGTCCGCCGTGCAGGC
3’F-PD2-XbaI ATCTCTAGAATGGGCACCTCGGCCACGCTGGCGCTG
3’R-PD2-NotI AAGTATGCGGCCGCATGAGCGAAACCCTGTTGAAAGTATC
CmF-BamHI CGCGGATCCTGATGTCCGGCGGTGCTTTTG
FHAproF-BamHI TCTGGATCCCTGCGCTGGCACCCGCGGCGGGCCG
FHAR-MCS GCCTCTAGATTCATATGATTCCGACCAGCGAAGTGAAGTAAT
PRNF-NdeI CTGGTCGGCATATGAACATGTCTCTGTCACGCATTG
PRNF ATGAACATGTCTCTGTCACGCATTGTCAAGG
PRNR-XbaI GCCTCTAGAGCCTGGAGACTGGCACCGGCCAAGC
PrnProF-BamHI CGGGGATCCGCACCCTGGCCTGCGGGGCGGGACC
PRNProR-NdeI AGACATGTTCATATGGATGCCAGGTGGAGAGCAGA
5’F-int CTAGCGTTCGCATACCAAATCCTTGC
5’RCM-int CCGTAATATCCAGCTGAACGGTCTGG
3’FCM-int TCTGTGATGGCTTCCATGTCGGCAG
3’R-int AGCATGTTGCGGTGTTCCCGGAATG
5’FPD-int ATGACGGAAAGCCGCATGGGCATTGGGTCC
3’RPD-int TTCGTACGTGTTCAGGTGCCGATTGCCGG
5’FPD2-int TGGGCTGGCTGTTCTGGCACGAAACG
3’RPD2-int TTCATCGAATCGGCGCTGATCCTGGC
PRNF-int AGGTGCAGCCATACATCAAGGCCAGC
Sequences with bold letters are the recognition sites for various restriction enzymes used for each construction. Underlined sequences are the sequences of the
new codons used for constructing mutant
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was generated by insertion of the ptx-ptl terminator next
to the S3 gene. The five structural genes of PT (modified
S1, S2, S4, S5, and S3) with its operon promoter were
amplified from Bp-WWC DNA using the primers PtxF-
BamHI and PtxR-MCS. The 3469 bp amplified product
was digested with BamHI and SpeI and the recovered
fragment was ligated into pSKΔRI cut with the same
enzymes to yield pSKptx. Plasmid pSKΔRI is a variant of
pBluescript II SK + where the EcoRI site has been
removed by digestion and filled-in with the Klenow
enzyme and re-circularized.
The ptx-ptl operon terminator was then amplified with
the TerF-EcoRI and TerR-SpeI primers. The 223 bp pro-
duct was doubly digested with EcoRI and SpeI and ligated
into pSKptx cut with the same enzymes. After transforma-
tion and colony selection, the resulting plasmid was desig-
nated as pSKptxter (Figure 3C). This plasmid was then
doubly digested with BamHI and SpeIa n dl i g a t e di n t o
pSSPD5Cm3 cut with the same enzymes to yield the con-
jugative vector pSSPDptxter. Allelic exchange into Bp-
PD53Cm was performed as described above with replica
screening for Sm
S and Cm
S colonies to obtain the strain
designated as Bp-WWD. The integration of S1 mutated
gene at the designated position was confirmed by PCR
with specific primers. The primers could bind the
upstream 5’ (5’FPD-int and R-R9K primers), 3’ (F-E129G
and 3’RPD-int primers) downstream flanking regions, and
internal S1 gene.
Insertion of a second copy of the prn structural gene
Integration of a chloramphenicol resistance gene into the
target site selected for integrating a second copy of the
PRN structural gene
A derivative of pBluescript SK + lacking the BamHI site
was constructed by digestion with the enzyme, filling-in
with the Klenow enzyme, and ligation. The resulting plas-
mid was transformed into E. coli and designated as
pSKΔH1.
The sequence of the B. pertussis Tohama strain was
scanned and pseudo-genes were identified. The DNA
sequence (posn. 1345693) between a putative exported
dehydrogenase (posn. 1344710-1345685) and a putative
aspartate racemase pseudo-gene (posn. 1345693-1346049)
was selected as the insertion site. These two genes carried
frameshift mutations and were not functional (Figure 5A).
The 5’-upstream region to the targeted insertion site was
amplified using primers carrying SpeI( 5 ’F-PD2-SpeI) and
a multilinker including BamHI and NotI( 5 ’R-PD2-MCS)
restriction sites. The amplified product was isolated by gel
electrophoresis and doubly digested with SpeIa n dNotI.
The resulting fragment was ligated into a fragment of
pSKΔH1 which was digested with the same enzymes. The
resulting plasmid was transformed into E. coli and
designated as pSKPD25. The 3’-downstream fragment was
similarly amplified with primers carrying XbaI(3’F-PD2-
XbaI) and NotI( 3 ’R-PD2-NotI) restriction sites. After
digestion with the same enzymes, the resulting fragment
was ligated into a fragment of pSKPD25 digested with the
same enzymes. The resulting plasmid was transformed
into E. coli and designated as pSKPD253.
The chloramphenicol resistance gene was obtained by
PCR amplification from plasmid pACYC184 using pri-
mers carrying a BamHI(CmF-BamHI) and XbaI( C m R -
XbaI) restriction site. The PCR product was digested
with the two enzymes and cloned into pSKPD253 cut
with the same enzymes. After ligation, the resulting
plasmid was transformed into E. coli, verified by restric-
tion analysis and designated as pSKPD25Cm3. The plas-
mid was digested with NotIa n dSpeI and the resulting
fragment was ligated into pSS4245 which was doubly
digested with the same enzymes. The resulting plasmid
was designated as pSSP2D5Cm3 and transformed into
E. coli SM10. Conjugation was conducted as described
a b o v eb yu s i n gB p - W W Da st h er e c i p i e n tB. pertussis
strain with selection of Cm
R and Sm
S single colonies.
The integration of Cm
R gene at its designated position
was confirmed by PCR with the primers that specifically
bind to only the upstream 5’ (5’FPD2-int and 5’RCM-int
primers), 3’ (3’FCM-int and 3’RPD2-int primers) down-
stream flanking regions, and inside the Cm
R gene.
Integration of prn gene under control of fha promoter
The structural gene of PRN was amplified from B. pertus-
sis DNA using a primer starting at the ATG start codon
(F) and a primer carrying an XbaI (R) restriction site. The
2,808 bp amplified product containing only the coding
region and the terminator was treated by an ‘A’ tailing
protocol (Promega, USA). The resulting fragment was
cloned into pGEM-T easy vector to obtain a plasmid
designated as pGEM-TPRN which was verified by restric-
tion analysis. In an initial workup to create a second copy
of the PRN gene driven by the stronger FHA promoter,
the FHA promoter was isolated from B. pertussis DNA by
PCR amplification and inserted ahead of the PRN gene.
The FHA promoter was amplified by primers carrying the
BamHI (FHAproF-BamHI) and a polylinker containing
NdeI-XbaI (FHAR-MCS). The purified product was cut
with BamHI and XbaI then the recovered DNA fragment
was ligated into pSKPD253 cut with the same enzymes.
The resulting plasmid designated as pSKPD253Fp was ver-
ified by restriction analysis. This plasmid was cut with
NdeIa n dXbaI, then ligated with the PCR product of the
prn gene which was amplified from pGEMTPRN by
PRNF-NdeI and PRNR-XbaI primers and cut with the
same enzymes. The resulting plasmid was designated as
pSKPD25FpPRN3 (Figure 5B). The conjugative construct
was obtained by digesting this plasmid with NotIa n dSpeI
and ligation into pSS4245 digested with the same enzymes.
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This construct was inserted at the selected location of the
Bp-WWD chromosome to replace the chloramphenicol
resistance marker introduced using the usual allelic-
exchange procedures and screening as described above.
Expression of prn gene under control of prn promoter
The PRN promoter was cloned by PCR amplification of
the B. pertussis DNA using primers with the restriction
sites BamHI( P r n P r o F - B a m H I )a n dNdeI( P R N P r o R -
NdeI). The plasmid pSKPD25FpPRN3 was cut with
BamHIa n dNdeI to generate a fragment which had lost
the FHA promoter. The PRN promoter was ligated in its
place. After transformation into E. coli and verification by
restriction analysis, the resulting plasmid was designated
as pSKPD25PRN3 (Figure 5C). The plasmid was cut with
NotI and inserted into pSS4245 cut with the same enzyme.
The resulting construct, pSSPD2prn was transferred into
E. coli SM10 to conduct the allelic exchange. The resulting
B. pertussis strain was designated as Bp-WWE. Integration
of the prn gene at its designated position was confirmed
by PCR with the primers that specifically bind only to the
upstream 5’ (5’FPD2-int and PRNProR-NdeI primers), 3’
(PRNF-int and 3’RPD2-int primers) downstream flanking
regions, and inside the prn gene.
PT, FHA and PRN expression in shake flask culture
The Bp-WWC, Bp-WWD and Bp-WWE strains were
grown in shake flasks with 100 mL MSS medium supple-
mented with methylated b-cyclodextrin (1 g/l) at 35°C
with shaking speed of 200 rpm. After 32-48 h of growth,
the culture supernatants were collected and assayed by
ELISA to quantify the PT and FHA expression level. As
PRN releasing from its membrane-bound precursor is the
result of an imprecise cleavage by unidentified proteases
[34], PRN expression was determined by Western blot
with densitometric analysis to evaluate the integrity of the
antigen. This assay was conducted both on the clarified
culture supernatant and the cell extract obtained by heat-
ing cell suspension in isotonic buffer (10 mM Tris-HCl
pH 8.0, 150 mM NaCl, 0.002% NaN3,a n d1m MP M S F )a t
60°C for 30 min and the supernatant was collected after
centrifugation at 10,000 × g, 4°C for 30 min.
ELISA assay for PT and FHA
Purified rabbit polyclonal antibodies against PT or FHA
(NLAC, Thailand) with the dilution of 1:1000 in carbo-
nate/bicarbonate buffer (pH 9.6) were coated in 96-well
plates (NUNC Maxisorp, Denmark) for 100 μLp e rw e l l
and incubated overnight at 4°C. After 3 time-washing with
phosphate-buffered saline pH 7.4 containing 0.1% Tween
20 (PBST), blocking was performed using 100 μL per well
of 3% bovine serum albumin (BSA)-PBST then incubated
at 37°C for 1 h. After discarding the blocking buffer and
washing, dilutions of the standard PT, FHA or samples
were loaded and incubated at 37°C for 1 h. Then, anti-PT
mouse monoclonal antibody (Abcam, USA) at 1:30,000
dilution or anti-FHA mouse monoclonal antibody
(NIBSC, UK) at 1:10,000 dilution in blocking buffer was
added and incubated under the same conditions. After
washing the wells for three times with PBST, 100 μLo f
rabbit anti-mouse (H + L) IgG-HRP conjugate (Abcam,
USA) in blocking buffer at 1:10,000 dilution was used as
secondary antibody and incubated for 37°C for 1 h. After
washing with PBST, 100 μL of enzyme substrate, 3,3’,5,5’-
tetramethylbenzidine (KPL, USA), was added. The colour
reaction was terminated with 1 N HCl, 100 μL per well.
Optical density was measured at 450 nm using a microti-
ter plate reader. ELISA assay for PT and FHA of each
recombinant strain was done in three replicates using
three independent cultures.
Western blot assay for PRN
Dilutions of standard PRN and samples were resolved in a
10% SDS-PAGE gel then transferred to a PVDF mem-
b r a n eu s i n gas e m i - d r yb l o t t ing system. The membrane
was blocked with 5% skim milk in PBST for 1 h. After dis-
carding the blocking solution, the membrane was incu-
bated with 20 mL anti-PRN sheep serum (NIBSC, UK) at
1:10,000 dilution in blocking buffer for 1 h, then washed
three times with PBST. The membrane was then incu-
bated under the same conditions with 20 mL of rabbit
anti-sheep IgG-HRP conjugate (Santa Cruz Biotechnology,
USA) and washed again. The membrane was then
immersed in 3,3’-diaminobenzamidine until the brown
colour developed. The reaction was terminated by rinsing
2-3 times with de-ionized water, then left to dry at room
temperature. Western blot of PRN of the three recombi-
nant strains was performed in three replicates using cell
extracts from three independent cultures of each strain.
The membranes were scanned and converted to a picture
file. PRN concentrations were derived by densitometric
a n a l y s i so ft h es a m p l ea n dr e f e r e n c eb a n d su s i n gI m a g e J
software http://rsbweb.nih.gov/ij/.
Genetic stability
The strains were cultured in 100 mL MSS medium at 35°C
and agitated at 200 rpm for 48 h, then 0.1 mL of culture
was transferred into 100 mL MSS and incubated under
the same conditions. This step was repeated four more
times. Each transfer corresponded to 50 generations. The
culture was diluted and plated on MSS agar. Thirty iso-
lated colonies of a final plating were randomly picked and
analysed by PCR to detect the expected presence of ptx
and prn inserts.
CHO cell-clustering assay
CHO cell clustering activity was determined by the
method of Hewlett et al. [28] In short, CHO cells were
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Page 14 of 16cultured in the cRPMI 1640 medium supplemented with
10% fetal bovine serum. The cells were incubated at
37°C under 5% CO2 atmosphere. After trypsinization,
200 μL of CHO cell suspension at density of 2 × 10
4
cells/mL were seeded in a 96-well micro-culture plate.
Test samples and reference PT toxin were serially
diluted at ten-fold intervals in phosphate-buffered saline
( P B S )p H7 . 4a n da2 5μL volume of the dilutions was
added to each well. After incubation for 48 h under the
same conditions to permit maximal clustering, cells
were stained with crystal violet and photographed.
Abbreviation
P T :P e r t u s s i st o x i n ;P R N :P e r t a c t i n ;F H A :F i l a m e n t o u s
hemagglutinin; rPT: recombinant Pertussis toxin; ELISA:
Enzyme-Linked Immunosorbent Assay
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